Equity Overview
Price & Market Data
Price: $9.28
Daily Change: +$0.02 / 0.22%
Range: $9.03 - $9.30
Market Cap: $93,982,272
Volume: 17,851
Performance Metrics
1 Week: 1.20%
1 Month: 1.20%
3 Months: 41.68%
6 Months: -21.73%
1 Year: -36.07%
YTD: 38.92%
Company Details
Employees: 128
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. OptiNose, Inc.was founded in 2000 and is headquartered in Yardley, Pennsylvania.